Purolite Life Sciences today announced a new state of the art facility that will produce agarose resins based on technology developed at Llantrisant, which is Purolite’s R&D Centre of Excellence. Agarose resins are an integral technology used by pharmaceutical developers in the manufacture of modern monoclonal medicines targeting the treatment of cancer, rheumatoid arthritis and well known age related diseases.  The market MAbs continues to grow, with worldwide revenues in 2015 exceeding $85 billion. For 35 years Purolite, a US…